Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Size & Share, by Therapy Type (Chemotherapy, Immunotherapy, Radiotherapy, Hormonal Therapy); Application (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2884
  • Published Date: Mar 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Astellas Pharma Inc.
    • Clovis Oncology, Inc.
    • Johnson & Johnson Health Care Systems Inc.
    • Bayer AG
    • Orion Corporation
    • Merck & Co., Inc.
    • Novartis AG
    • AstraZeneca PLC


In-the-news

In The News

  • Astellas Pharma Inc. to conduct clinical trials to develop cell therapy. The development pipeline of the company includes high unmet medical needs such as autoimmune & cardiovascular diseases and cancer. The cell therapy research of the company is based on pluripotent stem cells (PSC)

  • Clovis Oncology, Inc. to present data from Phase 3 trial, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy inmCRPC Associated with Homologous Recombination Deficiency (HRD)”. The trial is associated with men with metastatic castration-resistant prostate cancer.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2884
  • Published Date: Mar 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of prostate cancer and growth in the investment and R&D activities in oncology are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2035.

Expensive nmCRPC treatment therapies and lack of awareness about the disease in lower economic regions are estimated to be the growth-hindering factors for market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Astellas Pharma Inc., Clovis Oncology, Inc., Johnson & Johnson Health Care Systems Inc., Bayer AG, Orion Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca PLC, and others.

The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by therapy type, application, and by region.

The hormonal therapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying